Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients.

Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue JY, Gatto S, Fernandez-Banet J, Pavlicek A, Velastegui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Janne PA, Olson P, Christensen JG.

Cancer Discov. 2019 Oct 28. pii: CD-19-1167. doi: 10.1158/2159-8290.CD-19-1167. [Epub ahead of print]

PMID:
31658955
2.

Ultraviolet and light absorption spectrometry.

Howell JA, Hargis LG.

Anal Chem. 1994 Jun 15;66(12):445R-461R. Review. No abstract available.

PMID:
8092474
3.

Ultraviolet and light absorption spectrometry.

Howell JA, Hargis LG.

Anal Chem. 1990 Jun;62(12):155R-69R. doi: 10.1021/ac00211a006. No abstract available.

PMID:
20527849
4.

Ultraviolet and light absorption spectrometry.

Hargis LG, Howell JA.

Anal Chem. 1988 Jun 15;60(12):131R-146R. Review. No abstract available.

PMID:
3046418

Supplemental Content

Loading ...
Support Center